Merck/Medco Model Returns – At The PBM Management Level
Executive Summary
Former tops execs at GSK and Lilly are going to try their hand at running PBMs. If they need advice, they can ask their predecessors from the 1990s, when big pharma ran the big three PBMs.
You may also be interested in...
Rx Import Legislation: One Step Forward, Two Steps Back – And Odd Dance Partners
The strange politics of prescription drug importation legislation in the US are on display again, this time in the context of the FDA user fee reauthorization bill. Including the topic in the bill is a ‘big deal’ – but probably makes imports less likely.
US COVID Vaccine Authorizations: Too Much – Or Never Enough?
A US FDA advisory committee review of a novel COVID vaccine candidate from Novavax made one thing very clear: The agency is firmly convinced that when it comes to vaccine options, more is better.
US FDA Commissioner Califf’s Baptism By Fire – Or, At Least, Formula
Robert Califf’s second tenure as FDA commissioner already feels different from the first, thanks to a national shortage of infant formula – and an abundance of questions about what FDA could have done to prevent it.